www.fdanews.com/articles/158315-novartis-afinitor-not-cost-effective-says-nice

Novartis' Afinitor Not Cost Effective, Says NICE

September 2, 2013

Cost regulators for the NHS in England and Wales have confirmed that patients with advanced breast cancer will not be able to routinely access Novartis' Afinitor.
Pharma Times